Promising Results For Qilu Pharmaceuticals' Iparomlimab And Tuvonralimab In Cervical Cancer Clinical Trial

In a significant development in the field of gynecological oncology, the European Society of Gynecological Oncology (ESGO) 2024 Conference has spotlighted a groundbreaking study on cervical cancer treatment. The study, encapsulated in abstract #251, was chosen for oral presentation on March 8, showcasing the promising results of a Phase II clinical trial named DUBHE-C-206. This trial assessed the efficacy and safety of Qilu Pharmaceuticals' innovative combination therapy, iparomlimab and tuvonralimab (QL1706), in treating cervical cancer. The full details of the abstract are accessible online for those interested in the intricate findings of this research.

Under the leadership of Professor Jihong Liu from Sun Yat-sen University Cancer Center and Professor Hanmei Lou from Zhejiang Cancer Hospital, this pivotal study embarked on a mission to offer new hope to patients battling recurrent or metastatic cervical cancer. Specifically targeting those who had not responded to first-line platinum-based chemotherapy, with or without bevacizumab, and had not undergone prior immunotherapy, the trial presented an alternative therapeutic avenue.

The multi-center, single-arm Phase II study spanned across 38 medical centers in China and enrolled 148 patients. With a median follow-up period of 11.0 months at the data cut-off point, the trial meticulously evaluated the outcomes of administering QL1706 at a dose of 5.0 mg/kg every three weeks (Q3W).

The primary endpoint of the study was the objective response rate (ORR), which was impressively met with a 33.8% success rate as assessed by an Independent Evaluation Committee (IRC). Furthermore, the disease control rate (DCR) stood at 64.9%, and the median progression-free survival (PFS) was recorded at 5.4 months. Notably, overall survival (OS) data had not been reached at the time of reporting.

However, like all treatments, QL1706 was not without its side effects. Treatment-related adverse events (TRAEs) were observed in 70.3% of subjects, with 24.3% experiencing grade ≥3 TRAEs. Anemia was identified as the most common TRAE at a rate of 4.1%. Despite these challenges, treatment discontinuation due to TRAEs was relatively low, affecting only three patients (2.0%). Importantly, there were no TRAE-related deaths reported.

A New Horizon for Cervical Cancer Treatment

This clinical trial marks a significant milestone in cervical cancer treatment, demonstrating that QL1706 is both an effective and safe therapy option for patients with recurrent or metastatic cervical cancer who have exhausted first-line treatments. The acceptance of the new drug application for QL1706 by China's NMPA Center for Drug Evaluation (CDE) in August 2023 further underscores its potential as the first MabPair product targeting PD-1 and CTLA-4 worldwide.

As the global medical community continues to search for more effective treatments for cancer, studies like DUBHE-C-206 offer a glimmer of hope to those affected by this devastating disease. With ongoing research and clinical trials, there is an optimistic outlook for improving patient outcomes in cervical cancer and beyond.